Mark R. Fesen

Learn More
This is the first randomized, open-label, multicenter trial designed and powered to directly compare the hemoglobin (Hb) response to epoetin alfa (EPO), 40,000 U once weekly (QW), with that to(More)
PURPOSE To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS The study design was a phase III, open-label,(More)
8153 Background: Epoetin alfa (EPO) and darbepoetin alfa (DARB) both decrease transfusion requirements and increase hemoglobin (Hb) in anemic cancer patients (pts) receiving chemotherapy (CT). (More)